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ALTERED CIRCULATING FOLLICULAR HELPER T CELL PHENOTYPE IN
SYSTEMIC LUPUS ERYTHEMATOSUS. John H. Ho, Jin-Young Choi, and Joseph E.
Craft. Section of Rheumatology, Department of Internal Medicine, Yale University,
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Autoreactive	
  B	
  cells	
  in	
  Systemic	
  Lupus	
  Erythematosus	
  (SLE)	
  undergo	
  

autoantigen	
  selection,	
  suggesting	
  a	
  requirement	
  for	
  germinal	
  center	
  follicular	
  helper	
  
T	
  (Tfh)	
  cells	
  in	
  their	
  maturation.	
  	
  However,	
  evidence	
  for	
  dysregulation	
  of	
  Tfh	
  cells	
  in	
  
SLE	
  and	
  their	
  contribution	
  to	
  disease	
  activity	
  remains	
  unclear.	
  	
  Recently,	
  blood	
  
CXCR5hi	
  CD4	
  T	
  cells,	
  a	
  heterogeneous	
  pool	
  consisting	
  of	
  functionally	
  distinct	
  Th1-‐,	
  
Th2-‐,	
  Th17-‐like	
  subsets,	
  have	
  been	
  proposed	
  to	
  be	
  the	
  circulating	
  counterpart	
  of	
  Tfh	
  
cells.	
  	
  The	
  purpose	
  of	
  this	
  study	
  was	
  to	
  examine	
  the	
  hypothesis	
  that	
  Tfh	
  
dysregulation,	
  as	
  reflected	
  in	
  altered	
  phenotype	
  of	
  blood	
  CXCR5hi	
  population,	
  was	
  
associated	
  with	
  SLE	
  disease	
  activity.	
  	
  Blood	
  samples	
  from	
  49	
  clinically	
  well-‐
characterized	
  SLE	
  patients,	
  28 Behçet's disease (BD) patients as autoimmune disease
control and 16 healthy controls were included. Expression of key Tfh surface receptors
(ICOS, inducible T-cell co-stimulator; PD-1, programmed cell death protein-1) as well as
composition of T helper subtypes within the circulating CXCR5hi compartment were
enumerated by flow-cytometry. The phenotype of blood CXCR5hi cells was correlated
with clinical history and B cell phenotype. SLE patients had significant expansion of
circulating Tfh-like CD4 T cells (CXCR5hiICOShiPD-1hi) when compared to controls (p <
0.001). Interestingly, PD-1 mean florescence intensity (MFI) was markedly elevated in
blood CXCR5hi subset of SLE patients when compared to controls (p < 0.001). PD-1
MFI in the CXCR5hi population correlated significantly with SLE disease activity index
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(SLEDAI; Spearman r = 0.43, p = 0.03), blood plasmablast expansion (Spearman r =
0.34, p = 0.02), and high anti-dsDNA antibody titers (p = 0.004). Blood CXCR5hiPD-1hi
cells phenotypically resembled pre- or post-germinal center Tfh cells, with increased
percentage of IL-21 producers (p = 0.02), lower CCR7 MFI (p = 0.03) when compared to
CXCR5hiPD-1lo subset, and low Bcl-6 expression. Compared to BD patients, SLE
patients had an increase in the CXCR5hi Th2 subset (p < 0.05) and a decrease in the Th17
(p < 0.001) subsets. The expansion of the CXCR5hi Th2 subset was also positively
associated with SLEDAI scores. Our results demonstrate that altered phenotype and
subset composition of blood Tfh-like cells is correlated with disease activity in lupus
patients, suggesting a potential role of GC Tfh dysregulation in the pathogenesis of
human SLE.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune disease marked by
immune complex-mediated tissue injury in multiple vital organs1. The clinical
manifestations and the underlying immunoregulatory factors that contribute to disease
expression are diverse2. Such heterogeneity poses a significant challenge for both
clinical management and development of targeted therapeutics. Thus, there is a need to
identify the common pathogenic cellular pathway that leads to lupus disease activity in an
effort to define rational therapeutic targets.
The presence of autoantibodies is a common phenotype of SLE and their
pathological role in lupus has been confirmed in animal models and clinical studies3. The
collaboration between germinal center (GC) CD4 T cells and B cells, via processes such
as high-affinity B cell selection and B cell memory induction, is central to the production
of autoantibodie4,5. This is evidenced by the fact that pathogenic autoantibodies in SLE
are high-affinity, somatically mutated, and Ig-switched antibodies that have undergone
selection by T cells6-8. In addition, spontaneous formation of GCs has been documented
in a mouse model of SLE9. Furthermore, intensive GC activity has been shown in
patients with active lupus nephritis10. Taken together, these data point to a vital role of
GC T cells in the pathogenesis of SLE.
Follicular helper T (Tfh) cells have been established as the specialized T cell
subset responsible for the development of B cell response in the GC11. Tfh cells are
positioned in the B cell follicles of secondary lymphoid organs and are identified by a
combination of cellular markers, including	
  CXCR5,	
  the	
  chemokine	
  receptor	
  that	
  
enables	
  the	
  migration	
  of	
  Tfh	
  cells	
  toward	
  B	
  cell	
  follicles12,13;	
  ICOS,	
  a	
  co-‐stimulatory	
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molecules	
  important	
  for	
  the	
  helper	
  function	
  of	
  Tfh	
  cells14;	
  and	
  PD1,	
  a	
  surface	
  
molecules	
  classically	
  known	
  to	
  provide	
  inhibitory	
  signals	
  to	
  the	
  T	
  cells15,	
  but	
  which	
  
also	
  regulate	
  GC	
  B	
  cell	
  survival16.	
  	
  	
  Functionally,	
  Tfh	
  cells	
  also	
  secrete	
  key	
  cytokines	
  
that	
  promote	
  growth,	
  differentiation,	
  and	
  antibody	
  class-‐switching	
  of	
  B	
  cells,	
  such	
  as	
  
IL-‐4	
  and	
  IL-‐2116-‐18.	
  	
  Importantly,	
  the	
  expansion	
  of	
  Tfh	
  cells	
  is	
  associated	
  with	
  the	
  
development	
  of	
  systemic	
  autoimmunity	
  in	
  animal	
  studies19,20.	
  	
  The	
  expansion	
  of	
  Tfh	
  
cells	
  has	
  also	
  been	
  causally	
  linked	
  to	
  the	
  abundance	
  of	
  GCs,	
  production	
  of	
  
autoantibodies,	
  and	
  end-‐organ	
  damage	
  in	
  a	
  mouse	
  model	
  of	
  SLE21.	
  	
  Thus,	
  in	
  animal	
  
models	
  of	
  lupus,	
  Tfh	
  cells	
  are	
  centrally	
  involved	
  in	
  the	
  cellular	
  pathway	
  that	
  lead	
  to	
  
clinical	
  disease.	
  
While	
  the	
  involvement	
  of	
  Tfh	
  cells	
  in	
  animal	
  models	
  of	
  SLE	
  has	
  been	
  shown,	
  
evaluation	
  of	
  Tfh	
  cells	
  in	
  human	
  SLE	
  has	
  been	
  limited	
  by	
  the	
  inability	
  to	
  routinely	
  
study	
  secondary	
  lymphoid	
  tissues	
  in	
  patients.	
  	
  Recently,	
  however,	
  studies	
  have	
  
shown	
  that	
  circulating	
  CXCR5hi	
  CD4	
  T	
  cells	
  are	
  circulating	
  counterparts	
  of	
  Tfh	
  
cells22.	
  	
  	
  In	
  ICOS-‐	
  and	
  CD40L-‐deficient	
  patients,	
  there	
  are	
  impaired	
  GC	
  formations	
  
and	
  the	
  absence	
  of	
  circulating	
  CXCR5hi	
  subset23.	
  	
  Conversely,	
  expansion	
  of	
  blood	
  
CXCR5hi	
  population	
  has	
  been	
  noted	
  post-‐immunization	
  in	
  humans24.	
  	
  In	
  another	
  
recent	
  study,	
  CXCR5hi	
  subset	
  is	
  shown	
  to	
  efficiently	
  induce	
  naïve	
  B	
  cell	
  
differentiation	
  and	
  Ig	
  type	
  switch	
  via	
  secretion	
  of	
  key	
  Tfh	
  cytokines	
  in	
  vitro,	
  
demonstrating	
  that	
  they	
  indeed	
  share	
  functional	
  properties	
  with	
  Tfh	
  cells25.	
  	
  Thus,	
  
blood	
  CXCR5hi	
  CD4	
  T	
  cells	
  appears	
  to	
  be	
  an	
  attractive	
  biomarker	
  to	
  study	
  GC	
  Tfh	
  
dysregulation	
  in	
  lupus.	
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Recently,	
  the	
  expansion	
  of	
  blood	
  CXCR5hiICOShi	
  or	
  CXCR5hiPD1hi	
  subset	
  has	
  

been	
  found	
  in	
  a	
  subset	
  of	
  SLE	
  patients	
  with	
  severe	
  end-‐organ	
  involvement26.	
  	
  
However,	
  the	
  relationship	
  between	
  blood	
  CXCR5hi	
  population	
  and	
  SLE	
  disease	
  
activity	
  has	
  not	
  been	
  demonstrated.	
  	
  In	
  addition,	
  CXCR5hi	
  CD4	
  T	
  cells	
  appear	
  to	
  be	
  
heterogeneous	
  and	
  can	
  be	
  functionally	
  grouped	
  into	
  Th1-‐,	
  Th2-‐,	
  and	
  Th17-‐like	
  
cells25.	
  	
  Importantly,	
  CXCR5hi	
  Th2	
  and	
  Th17,	
  but	
  not	
  Th1,	
  subset	
  have	
  the	
  capability	
  
to	
  provide	
  B	
  cell	
  help,	
  and	
  the	
  skewed	
  composition	
  of	
  CXCR5hi	
  CD4	
  T	
  cell	
  subsets	
  
may	
  contribute	
  to	
  autoimmunity25.	
  	
  Whether	
  the	
  composition	
  of	
  blood	
  CXCR5hi	
  cells	
  
in	
  human	
  SLE	
  is	
  altered	
  remains	
  unknown.	
  	
  In	
  an	
  effort	
  to	
  elucidate	
  the	
  involvement	
  
of	
  Tfh	
  cells	
  in	
  SLE	
  disease	
  activity,	
  we	
  examined	
  the	
  surface	
  phenotype	
  and	
  subset	
  
heterogeneity	
  of	
  blood	
  CXCR5hi	
  cells	
  of	
  SLE	
  patients.	
  	
  	
  We	
  further	
  correlated	
  altered	
  
CXCR5hi	
  cell	
  phenotype	
  with	
  clinical	
  history,	
  SLE	
  disease	
  activity,	
  and	
  pathological	
  B	
  
cell	
  activity.	
  	
  Lastly,	
  we	
  evaluated	
  key	
  Tfh	
  cytokine	
  secretion,	
  gene	
  expression	
  and	
  
surface	
  molecules	
  of	
  blood	
  CXCR5hi	
  cells	
  in	
  order	
  to	
  establish	
  the	
  functional	
  
relationship	
  between	
  blood	
  CXCR5hi	
  cells	
  and	
  GC	
  Tfh	
  cells.	
  

	
  
THESIS HYPOTHESIS	
  
We hypothesized that the phenotype and subset composition of circulating Tfh-like
CXCR5hi CD4 T cells are altered in human SLE, and that such alterations are associated
with disease activity and pathological B cell activity, supporting a potential role of Tfh
cells in the pathogenesis of SLE.

8	
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METHODS
Study populations. We analyzed blood samples from two adult cohorts. The first, from
the Faculdade de Medicina, Universidade de São Paulo, included 49 SLE patients (46
female and 3 male; median age 37 years, range 30-48 years; 32 Caucasian, 17 nonCaucasian), 28 Behçet's disease (BD) patients (22 female and 6 male; median age 48
years, range 40-56 years; 20 Caucasian, 8 non-Caucasian), and 16 healthy controls (12
female and 4 male; median age 28 years, range 27-32 years; 13 Caucasian, 3 nonCaucasian). Their characteristics are shown in Table 1. We also studied samples from 9
patients with SLE (8 female and 1 male; median age 40 years, range 26-63 years, 4
Caucasian, 5non-Caucasian) from Yale-New Haven Hospital (YNHH), with their data
shown in Figure 4. SLE patients fulfilled American College of Rheumatology (ACR)
criteria with disease activity assessed by the SLE Disease Activity Index, whereas BD
patients met BD criteria set on International Study Group for Behcet’s Disease. Informed
consent was obtained from all subjects. This study was approved by the institutional
review committees of the Faculdade de Medicina, Universidade de São Paulo and Yale
University.
Flow cytometry. We isolated peripheral blood mononuclear cells (PBMC) using
density-gradient centrifugation on Ficoll-Paque with single cell suspensions stained with
the following antibodies: Alexa Fluor 700-conjugated CD4, V450-conjugated CD45RA
and CD27, PE-conjugated PSGL1 and CD4, PE-Cy7-conjugated PD-1, CCR7, and IgD,
Alexa Fluor 647-conjugated CXCR5 and IL-21, Fluorescein isothiocyanate (FITC)conjugated CD62L, APC-Cy7-conjugated CD19, PE-Cy5-conjugated CD38, and
streptavidin-conjugated APC-Cy7 (all from Becton Dickinson (BD) PharMingen except
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FITC-conjugated ICOS and PE-CY5 conjugated TCR (eBioscience). Fluorescencelabeled cells were collected by multiparameter flow cytometry (LSRFortessa or LSR II;
BD), with exclusion of doublets by forward and side scatter and analyzed with FlowJo
software (Tree Star, Ashland, OR). CD45RA- activated CD4 cells divided to CXCR5hi
and CXCR5lo cells (Figure 1A, left panel), and circulating Tfh-like cells were identified
by high expressions of PD-1 and ICOS among CXCR5hi cells (Figure 1B, top right
quadrants of left and middle panel); the expression of each molecule gated on the basal
expression of PD-1 (< 0.5%) and ICOS (< 0.5%) on naïve CD45RA+ CD4+ T cells from
healthy control, and subsequent double positive population of ICOShiPD-1hi (< 0.1%)
(Figure 1A, right panel).
Intracellular IL-21 staining. PBMC stained with surface markers were stimulated with
PMA (50 ng/ml) and ionomycin (1 g/ml) for first 2 hours then in the presence of golgi
plug (BD) for last 2 hours. Cells were fixed with BD CytoFix/CytoPerm and
permeabilized with BD PERM/ Wash solution, followed by staining with anti IL-21.
Stained cells were collected by multiparameter flow cytometry (LSR II; BD), with
exclusion of doublets by forward and side scatter and analyzed with FlowJo software
(Tree Star, Ashland, OR).
Statistical analysis. All data are presented as the mean ± SEM. The significance of the
difference between groups was analyzed with one-way ANOVA test, with the
significance of difference between two groups evaluated by the two-tailed Student’s t
test. Spearman correlation coefficient or Pearson correlation coefficient with two-tailed p
value were determined in the analysis of correlations. P values less than 0.05 were

	
  
considered significant. Data were analyzed with Prism software (version 5.0d for
Macintosh; GraphPad Software).

11	
  

	
  

12	
  

RESULTS
Analysis of circulating cells with Tfh surface phenotype in SLE patients. CXCR5hi
Tfh cells in secondary lymphoid tissues express PD-1 and ICOS, surface molecules
central to their B cell helper function in the B cell follicles27. By contrast, previously
activated CXCR5hi CD4 T cells in the circulation of normal individuals are typically PD1lo and ICOSlo, suggesting that while these cells may be capable of entry in to B cell
follicles via CXCR5, they may be at a resting state28. To determine whether blood
CXC5hi cells carry key Tfh surface phenotype in lupus patients, we examined the
expression of PD-1 and ICOS in blood samples of 49 SLE patients, 28 BD patients
(autoimmune disease control), and 16 healthy controls. We analyzed single CD4+TCRβ+
cells, dividing them into naïve (CD45RA+), CXCR5lo (CD45RA-CXCR5lo), and
CXCR5hi (CD45RA-CXCR5hi) subsets, with additional gating on PD-1 and ICOS
according to their expression level on the naïve subset (Figure 1A, left panel). Naïve
CD45RA+ T cells were CXCR5lo and express basal level of ICOS and PD-1 (Figure 1A,
right panel). Consistent with previous reports, majority of blood CXCR5hi cells are PD1loICOSlo in healthy donors (Figure 1 B, right panel, representative example; Figure
1C)28. Compared with healthy control, there was a significantly higher percentage of
blood CXCR5hi cells in lupus patients carrying GC Tfh surface phenotype, eg. PD1hiICOShi (p < 0.001; Figure 1B, middle panel, blood CXCR5hi cells, representative
example; Figure 1B, right panel, Tonsil GC Tfh cells; Figure 1C). In BD patients, there
was no increased percentage of blood CXCR5hi cells expressing high levels of PD-1 and
ICOS, suggesting that the presence of circulating Tfh-like CXCR5hiPD-1hiICOShi cells in
lupus patients is not merely a function of systemic

	
  

Figure 1. Prevalence of circulating cells with Tfh phenotype in SLE, BD, and healthy
controls.
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autoimmunity (Figure 1C). We also noted a significant increase in the percentage of
ICOShiPD-1hi cells within the CXCR5lo subset in lupus patients (p < 0.001; Figure 1C).
However, there was a disassociation of PD-1 and ICOS MFI in the CXCR5lo subset
(Pearson r = 0.10, p = 0.59; Figure 1D left panel), whereas there was a significant
correlation of their expression in the CXCR5hi subset (Pearson r = 0.38, p = 0.03; Figure
1D right panel). Thus, CXCR5hi subset, but not CXCR5lo subset, resembles GC Tfh cells
per analysis of surface receptor phenotype.

Figure 2. Expression of Tfh surface receptors in differential subsets of circulating CD4 T
cells in SLE, BD, and healthy controls.

	
  

15	
  
We next asked if a single Tfh-related surface receptor was selectively upregulated

in lupus patients. ICOS	
  is	
  a	
  co-‐stimulatory	
  molecule	
  important	
  for	
  the	
  helper	
  function	
  
of	
  Tfh	
  cells14.	
  	
  Previous	
  studies	
  have	
  found	
  an	
  increase	
  in	
  circulating	
  CD4+ICOShi	
  
lymphocytes,	
  although	
  their	
  number	
  varied	
  significantly	
  depending	
  on	
  how	
  the	
  
fraction	
  was	
  defined	
  and	
  the	
  SLE	
  cohort	
  studied29-‐31.	
  	
  In	
  our	
  SLE	
  cohort,	
  we	
  did	
  not	
  
find	
  a	
  significant	
  increase	
  in	
  ICOS	
  MFI	
  in	
  blood	
  CXCR5hi	
  cells	
  (p	
  >	
  0.05;	
  figure	
  2A).	
  	
  
PD-‐1	
  is	
  another	
  key	
  Tfh	
  surface	
  receptor,	
  and	
  it	
  plays	
  an	
  integral	
  role	
  in	
  the	
  
formation	
  and	
  affinity	
  of	
  plasma	
  cells	
  in	
  the	
  context	
  of	
  GC	
  processes16.	
  	
  Interestingly,	
  
we	
  found	
  a	
  drastic	
  increase	
  in	
  PD-‐1	
  MFI	
  in	
  the	
  CXCR5hi	
  population	
  as	
  compared	
  to	
  
both	
  healthy	
  control	
  and	
  BD	
  patients	
  (p	
  <	
  0.001;	
  Figure	
  2B).	
  	
  PD-‐1	
  expression	
  was	
  
also	
  increased	
  in	
  the	
  CXCR5lo	
  subset,	
  but	
  its	
  PD-‐1	
  MFI	
  was	
  significantly	
  lower	
  than	
  
those	
  of	
  CXCR5hi	
  subset	
  (Figure	
  2B).	
  
Taken together, we have found a significant expansion of blood CXCR5hi cells
that are PD-1hiICOShi, akin to GC Tfh cells, in lupus patients. PD-1, a molecule known
for its role in GC B cell survival, but not ICOS, was selectively upregulated in the
CXCR5hi subset in lupus compared to healthy controls.

	
  

Figure 3. PD-1 expression on circulating CXCR5hi subset correlates with Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) and expansion of circulating
plasmablasts.
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Correlation between PD-1 expression on blood CXCR5hi cells and disease activity in
SLE. We next asked if altered phenotype of blood CXCR5hi cells, the circulating
counterpart of Tfh cells, correlated with SLE disease activity. We first examined the
relationship between the expansion of CXCR5hiPD-1hiICOShi cells and SLE disease
activity index (SLEDAI); however, we did not find a significant correlation between the
two variables (Spearman’s r = 0.26, p = 0.19; data not shown). Similarly, we did not find
significant correlations between the percentages of CXCR5hiPD-1hiICOShi cells and
organ involvement, as well as aberrant B cells activation. In addition, we did not find a
correlation between the percentage of CXCR5hi cells in CD4 T cells and SLEDAI
(Spearman’s r = -0.21, p = 0.28; Figure 3A).
We then asked whether differential expression of key Tfh surface receptors on
blood CXCR5hi cells is correlated with disease activity in human lupus. In the cohort of
SLE patients with active disease, we found a significant correlation between PD-1 MFI in
blood CXCR5hi subset and SLEDAI scores (Spearman r = 0.43, p = 0.03; Figure 3B).
Elevated PD-1 may merely reflect T cells activation32 that is common in active SLE;
however, this did not appear to be the case, as ICOS, a marker of activated T cells, and
the patients’ SLEDAI was not correlated (Spearman r = 0.16, p = 0.52; Figure 3C).
Moreover, there was no relationship between the percentage of activated CD45RA- CD4
T cells and SLEDAI (data not shown).
Given the association between PD-1 MFI on CXCR5hi cells and disease activity,
we also asked if the former was linked to organ involvement. In patients with concurrent
proteinuria and hematuria, compared those without, we found an increase in PD-1 MFI
on CXCR5hi cells (1911 vs. 1199, respectively; p = 0.02), as we did for patients with
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ongoing pyuria (2590 vs. 1200; p = 0.0007). By contrast, apart from serositits (1551 vs.
1087, p = 0.007), PD-1 did not correlate with past organ injury, including skin, joint,
kidney, CNS, and vasculature. These results in aggregate indicated that the PD-1 MFI on
CXCR5hi cells correlated with disease activity, including renal inflammation. Consistent
with this theme, we found that PD-1 MFI on the CXCR5hi CD4 T cell subset was
increased in patients with elevated anti-dsDNA antibody titers, when compared to
patients without such autoantibodies (1891 vs. 1169, respectively; p = 0.004), and
elevated hypocomplementemic patients (1862 vs. 1173, p = 0.006), with the latter
presumably reflecting consumption upon engagement by autoantibody-autoantigen
immune complexes as a feature of active SLE3.
Association between PD-1 MFI and expansion of circulating plasmablasts. The
correlation between PD-1 on circulating CD4+CXCR5hi T cells and anti-dsDNA antibody
titers and presumed complement consumption suggested that elevated expression of this
protein might also be correlated with aberrant B cell activation. PD-1 is also critical,
among other proteins, for Tfh-directed GC maturation and plasma cell genesis16. We
therefore purified lymphocytes from patients and controls, staining them with CD19, IgD,
and CD38 to assess the pool of the IgD-CD38hi plasmablasts33. Consistent with previous
reports34, we found an increase in the percentage of circulating plasmablasts in SLE
patients compared to healthy controls (Figure 3D). We also found that the PD-1 MFI
among CXCR5hi cells positively correlated with the expansion of plasmablast in lupus
patients (Figure 3E, left panel). Of note, the percentage of plasmablasts was similar
between SLE patients regardless of treatment (Figure 3E, right panel).
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Analysis of circulating CXCR5hiPD-1hi cells in human SLE patients. Since the
presence circulating CXCR5hi cells carrying high levels of PD-1 strongly correlated with
disease activity and pathological B cell activity in lupus, we next asked how the
CXCR5hiPD-1hi cells are differ from the CXCR5hiPD-1lo cells, and whether they exhibit
key characteristics of GC Tfh cells. IL-21 is a key cytokine secreted by Tfh cells, leading
to differentiation, proliferation, isotype switching of B cells17,18. We therefore examined
the presence of IL21-producing cells in circulating CXCR5hiPD-1hi CD4 T cells of lupus
patients. We sought CD4+CD45RA-CXCR5hi cells and divided them into PD-1lo and
PD-1hi subset to measure the percentage of IL-21 producing cells in each population
(Figure 4A, left panel; representative example). In lupus patients, we found a significant
higher proportion of IL21+ cells in the CXCR5hiPD-1hi subset compared to CXCR5hiPD1lo subset (p = 0.02; Figure 4A, right panel). The secretion of IL21 suggests that blood
CXCR5hiPD-1hi cells in lupus patients are functionally related to bona fide Tfh cells in
their capability to provide B cell-help signals.
Previously, circulating CXCR5hi CD4 T cells in healthy donors were found to
have a central memory phenotype, with high expression level of CCR7, which is required
for cell entry into secondary lymphoid organs28. In contrast, GC Tfh cells down-regulate
CCR7 in order to achieve proper follicular positioning. We therefore asked whether
blood CXCR5hiPD-1hi cells in lupus carried a central memory phenotype28 or a GC Tfhlike phenotype by analyzing their level of CCR7 expression. We compared CCR7 MFI
of CXCR5hiPD-1hi cells and CXCR5hiPD-1lo cells in the form of its relative expression to
CCR7 MFI on naïve CD45RA+CD4 T cells

	
  

Figure 4. Functional and phenotypic analysis of circulating CXCR5hiPD-1hi cells.
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(representative sample, figure 4B, left panel). Interestingly, we found a significant lower
CCR7 expression in CXCR5hiPD-1hi cells when compared to CXCR5hiPD-1lo cells.
Thus, blood CXCR5hiPD-1hi cells do not resemble the previously described circulating
CXCR5hi central memory population. Instead, it more resembles active Tfh cells in
secondary lymphoid organ based on memory marker analysis.
Bcl-6 is the key transcriptional factor that drives Tfh formation35-37. It is highly
expressed in GC Tfh cells38,39. In addition, its overexpression is sufficient to upregulate
CXCR5, PD-1, ICOS, and downregulate CCR7 in vitro and in vivo 35,36. Therefore, we
assessed Bcl-6 expression in blood CXCR5hiPD-1hi cells of lupus sample as compared to
naïve CD45RA+ CD4 T cells and CXCRhiPD-1hiICOShi Tfh cells from Tonsils of a nonlupus patient. We found that blood CXCR5hiPD-1hi cells in lupus express the basal level
of bcl-6 at a level similar to that of naïve CD4 T cells (representative sample, Figure 4C).
Taken together, our data supports a model in which follicular helper T cell
phenotype is altered in human systemic lupus erythematosus (Figure 5). In such model,
presentation of autoantigen by dendritic cells (DC) to T cells leads to the differentiation
of T helper (Th) cells and follicular helper T precursors (pre-Tfh) (1, Figure 5). Tfhdestined cells migrate to border of T-cell zones and B-cell follicles, where they contact
autoantigen-activated B cells (2, Figure 5). Subsequent migration of both subsets deeper
into the follicle leads to germinal center (GC) formation (3, Figure 5). GC Tfh cells are
notable for high CXCR5, PD-1, and Bcl6 expression, as well as production of IL-21. In
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Figure 5. Model of altered follicular helper T cell phenotype in systemic lupus
erythematosus.
the GC, Tfh cells promote class switching and affinity selection of B cells via secretion of
cytokine (eg. IL-21) and expression of cell bound molecules (eg. PD-1). The result is the
production of high-affinity autoantibody-secreting plasma cells, leading to pathology and
disease activity (4, Figure 5). In parallel, there is an expansion of Tfh-like cells in the
peripheral blood (5, Figure 5). Akin to Tfh cells, these Tfh-like cells also express high
levels of CXCR5, PD-1, and are enriched with IL-21 producers. The presence of
CXCR5hiPD-1hi Tfh-like cells in blood is associated with disease activity, plasmablast
expansion, and autoantibody production. Unlike GC Tfh cells, circulating Tfh-like cells
have low levels of Bcl6, indicating that they may have relocated to the periphery pre- or
post-germinal center reaction. Importantly, these circulating Tfh-like cells express low
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level of CCR7, which differentiate them from previously described circulating central
memory T cells with high level of CXCR528 (6, figure 5).
Differential composition of Tfh subsets in human SLE. Recently, human blood
CXCR5hi CD4 T cells was found to consist of three subsets (Th1, Th2, and Th17), based
on their cytokine production and chemokine receptor profile25. Notably, Th2 and Th17,
but not Th1, CXCR5hi CD4 T cells secrete IL-21 and promote differential antibody
secretion by naïve B cells in vitro25. Consistent with previous findings, we found that a
portion, but not all, of CXCR5hi CD4 T cells were IL-21 producers (Figure 4A). We
therefore asked if there is another dimension of Tfh dysregulation in human SLE,
namely, if the blood CXCR5hi subset composition was different among lupus patients and
our two control groups. We gated on circulating CD4+TCRβ+CD45RA-CXCR5hi
lymphocytes, using chemokine receptors (CXCR3, CCR4, and CCR6) to identify subsets,
with Th1 cells defined as CXCR3hiCCR4-CCR6lo, Th2 as CXCR3loCCR4hiCCR6lo, and
the Th17 subset as CXCR3loCCR4loCCR6hi (Figure 6A)25,40. Where as lupus patients had
a reduction of Th1 CXCR5hi cells compared to healthy donors, and a decrease in the
Th17 subset compared to BD patients (Figure 6B, left and right panel, respectively), we
found expansion of the CXCR5hi Th2 subset compared to BD patients, with a trend
toward an increase compared to healthy controls (Figure 6B, middle panel). Consistent
with the latter finding was the positive association between the frequency of CXCR5hi
Th2 cells and patients’ SLEDAI, an association that is not clearly observed with the Th1
and Th17 populations (Figure 6C).

	
  

Figure 6. Composition of circulating CXCR5hi subsets and its relationship with SLE
disease activity.
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DISCUSSION
SLE is an autoimmune disease characterized by the production of autoantibodies.
The pathogenic antibodies in SLE are isotype-switched, suggesting the involvement Tfh
cells in the GC response8. However, the involvement of Tfh cells in disease activity of
human SLE remains unclear. Blood CXCR5hi cells are attractive biomarkers to study
human Tfh dysregulation because they exhibit key functional and physical characteristics
of Tfh cells and have been proposed to be their circulating counterparts25. In addition,
expansion of blood CXCR5hiPD-1hi and CXCR5hiICOShi cells have been found in a
subset of SLE patients with severe end-organ involvement26.
CXCR5hi Tfh cells in secondary lymphoid tissues express high levels of PD-1 and
ICOS, surface molecules central to their B cell helper function27. In contrast, blood
CXCR5hi CD4 T cells in healthy individuals are PD-1loICOSlo, suggesting that while they
are capable of entry into B cell follicles via CXCR5, they may not be actively carrying
out Tfh functions28. Here, we report a significant increase of CXCR5hiPD-1hiICOShi cells
in SLE patients as compared to healthy controls. Such	
  expansion	
  was	
  not	
  seen	
  in	
  
Behçet's	
  disease,	
  demonstrating	
  that	
  it	
  was	
  not	
  merely	
  a	
  function	
  of	
  systemic	
  
inflammatory	
  disorder,	
  but	
  a	
  distinctive	
  phenotype	
  in	
  human	
  SLE.	
  	
  The	
  presence	
  of	
  
such	
  circulating	
  Tfh-‐like	
  cells	
  likely	
  reflect	
  germinal	
  center	
  dysfunction,	
  a	
  hallmark	
  
of	
  murine	
  lupus19-‐21,	
  and	
  one	
  likely	
  present	
  in	
  human	
  SLE,	
  as	
  evidenced	
  by	
  studies	
  
demonstrating	
  abnormal	
  GC	
  B	
  cell	
  selection41	
  and	
  circulating	
  GC	
  B	
  cells	
  in	
  patients	
  
with	
  active	
  disease42-‐44.
We have found that the combination of high CXCR5 and high PD-1 expression
effectively identifies circulating cells resembling pre- or post-GC Tfh cells in SLE
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patients. High expression of CXCR5 implies that these cells are capable of being
retained near B cells follicles in response to CXCL13 much like Tfh cells13,27. High
expression of PD-1 suggests that these cells have the capability to regulate GC B cell
survival16. These cells also express relatively higher amounts of ICOS as we found a
significant positive correlation between ICOS and PD-1 expression in CXCR5hi CD4 T
cells. The ICOS-ICOSL interaction between T cells and B cells has been shown to be
central in T-dependent antibody response, Ig switching, and GC formation45-47.
Importantly, blood CXCR5hiPD-1hi cells are enriched with IL-21 producers when
compared to CXCR5hiPD-1lo cells. IL-21 is a hallmark cytokine produced by Tfh cells,
and is important for the differentiation, proliferation, isotype-switching of B cells17,18,48.
Thus, blood CXCR5hiPD-1hi cells strongly resemble Tfh cells based on phenotypic and
functional analysis. We also found that circulating CXCR5hiPD-1hi cells expressed lower
level of Bcl-6 when compared to GC Tfh cells39,49. This result is consistent with previous
findings in blood CXCR5hiICOShi Tfh-like cells of lupus patients26. Our result implies
that blood CXCR5hiPD-1hi cells may be pre-GC Tfh cells. Alternatively, Bcl-6 may have
been down-regulated post-GC reaction in a manner analogous to decreased Bcl-6
expression level in post-GC B cells50, suggesting that these cells are post-GC Tfh cells
that have been dislocated into the periphery. The presence of these pre- or post-GC Tfhlike cells in the periphery strongly suggest that there is GC Tfh expansion or dysfunction
in human SLE – a consistent finding in multiple animal models of SLE19-21. In the future,
the relationship between blood CXCR5hiPD-1hi cells and GC Tfh cells may be further
clarified using, for instance, an IL-21 reporter mice system51.
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Importantly, the circulating CXCR5hiPD-1hi population in human SLE is distinct

from the previously described blood CXCR5hi central memory T (Tcm) cells28. We
found that blood CXCR5hiPD-1hi cells expressed low levels of CCR7, a key chemokine
receptor of memory T cells that control migration to secondary lymphoid organs52. Thus,
they did not resemble CXCR5hi Tcm cells phenotypically. The combination of high
CXCR5 and low CCR7 also implies that these cells are more similar to Tfh cells, rather
then Tcm cells, in their localization capability. This is because while CXCR5 expression
is sufficient for localization to the T-B border, CXCR5 expression is not sufficient for
Tfh cells to localize inside follicles53. In fact, high levels of CCR7 expression can block
T cell migration to the B cell zone54. Thus, Tfh cells needs to downregulate CCR7 in
order to migrate to T-B boundary region55, a phenotype consistent with the circulating
CXCR5hiPD-1hi cells in human SLE.
We have found that PD-1 MFI in blood CXCR5hi cells correlated significant with
disease activity in SLE patients with active disease. PD-1 MFI in CXCR5hi cells is a
composite value reflecting the shift from CXCR5hiPD-1lo Tcm cells to CXCR5hiPD-1hi
pre- or post-GC Tfh cells. It also reflects PD-1 expression level in CXCR5hiPD-1hi cells.
This raises the possibility that both the expansion of Tfh compartment and the degree of
PD-1 expression on Tfh cells may contribute to SLE disease activity and thus play a role
in lupus pathology.
With regards to the expansion of Tfh cells, such	
  phenotype	
  has	
  already	
  been	
  
causally	
  linked	
  to	
  the	
  abundance	
  of	
  GCs,	
  production	
  of	
  autoantibodies,	
  and	
  end-‐
organ	
  damage	
  in	
  a	
  mouse	
  model	
  of	
  SLE21.	
  	
  The	
  expansion	
  of	
  circulating	
  Tfh-‐like	
  cells	
  
has	
  also	
  been	
  associated	
  with	
  severity	
  of	
  end	
  organ	
  damage	
  in	
  human	
  SLE26.	
  	
  Our	
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results	
  show	
  for	
  the	
  first	
  time	
  that	
  such	
  phenotype	
  is	
  also	
  associated	
  with	
  disease	
  
activity.	
  	
  A previous report has found no relationship between SLE disease activity and
the expansion of Tfh-like CXCR5hiICOShi cells26. The two studies differ in the use of
PD-1 vs. ICOS to define blood Tfh-like cells. Here, we found that PD-1, but not ICOS,
was significantly upregulated in CXCR5hi cells of SLE patients when compared to
healthy controls and thus served as a better marker to differentiate Tfh-like cells from
CXC5hi Tcm cells. In concordance, previous studies have found that the number of
CD4+ICOShi cells varied significantly depending on how the fraction was defined and the
SLE cohort studied29-31. Furthermore, consistent	
  with	
  the	
  correlation	
  between	
  Tfh	
  
dysregualtion	
  and	
  SLE	
  disease	
  activity,	
  we	
  have	
  found	
  strong	
  association	
  between	
  
Tfh	
  dysregulation,	
  expansion	
  of	
  circulating	
  plasmablast,	
  production	
  of	
  
autoantibodies,	
  and	
  ongoing	
  kidney	
  injury.	
  	
  Together,	
  these	
  findings	
  suggest	
  that	
  
expansion	
  of	
  Tfh	
  cells	
  are	
  intimately	
  involved	
  in	
  SLE	
  disease	
  flares,	
  making	
  them	
  
possible	
  targets	
  for	
  monitoring	
  or	
  treating	
  an	
  increase	
  in	
  disease	
  activity.	
  	
  Further	
  
validation	
  with	
  longitudinal	
  studies	
  will	
  clarify	
  their	
  potential	
  usefulness	
  as	
  
biomarkers	
  of	
  disease	
  activity	
  and	
  as	
  a	
  therapeutic	
  target.	
  
Our	
  findings	
  suggest	
  that	
  the	
  degree	
  of	
  PD-‐1	
  expression	
  on	
  Tfh	
  cells	
  may	
  also	
  
contribute	
  to	
  GC	
  dysfunction	
  and	
  SLE	
  disease	
  activity.	
  	
  Indeed, PD-1 expression on
Tfh cells appears to play an important role in regulating GC cell survival16. Classically,
PD-1 is known as an inhibitory receptor associated with CD8 T cell exhaustion during
chronic viral infection15,56,57. However, PD-1 is highly expressed on GC Tfh cells54,58,59,
and GC B cells express PD-L1 and elevated PD-L216. Interestingly, mice deficient in
PD-1 or PD-1 ligands had worsened B cell response, with increased GC cell death and
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decreased Tfh cell cytokine production, such as IL-4 and IL2116. It is important to note
that PD-1 can provide bidrectional signaling through PD1-PDL1 or PDL2 complexes15,
and PD-1 may provide direct inductive signals from GC Tfh to GC B cells or affect
duration of T-B conjugates55,60. Though the loss of function of PD-1 has been studied in
the context of GC reaction16, conducting gain of function study in the future may help
dissecting the mechanism between elevated PD-1 expression on Tfh-like cells and SLE
disease activity. Of note, the upregulation of PD-1 on circulating CD4 T cells in SLE
patients did not appear to be a reflection of generalized T cell activation as we did not
find a correlation between the percentage of activated (CD45RA-) CD4 T cells and PD-1
expression (data not shown). Elevated PD-1 also did not appear to be merely a function
of systemic autoimmunity as there was no alteration of PD-1 expression in BD patients.
Multiple factors may have contributed to elevated PD-1 expression in Tfh-like cells.
First, there is increased IL-21 secretion in human SLE61, which is able to induce PD-1
expression62. Second, there is increased type 1 interferon signal in SLE63, which can
enhance humoral immunity and promote isotype switching in vivo, suggesting the
involvement of Tfh cells. IFN regulated-element has also been found upstream of PD-1
gene in mice and enhances PD-1 expression in CD4 T cells64. Lastly, elevated Tfh PD-1
may also be a reflection of repeated TCR stimulation via increased T-B contact in SLE15.
We showed that there is an altered composition of circulating Tfh subsets in SLE.
In both SLE and BD patients, there was an underrepresentation of CXCR5hi Th1 cells
compared to healthy controls. A similar observation has been reported in patients with
juvenile dermatomyositis25. As previously demonstrated, CXCR5hi Th1 cells lacked B
helper activity25, and therefore the expansion of non-Th1 Tfh cells may be a significant
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contributing factor to pathogenic autoantibody production in SLE. Interestingly, there
was differential expansion of CXCR5hi subsets in SLE vs. BD patients. SLE patients had
significantly higher CXCR5hi Th2 cells compared to BD, while BD patients had
significantly higher CXCR5hi Th17 cells compared to SLE. While both Th2 and Th17
Tfh subtypes help B cells and induce Ig switch, Th2 subset is better at inducing IgE
production while Th17 subset is better at inducing IgA production25. Thus, the
differential expansion of functional Tfh subset may shape the characteristics of antibody
response in a disease specific manner.
In conclusion, our data show an expansion of circulating pre- or post-GC Tfh cells
in human SLE. The expansion of Tfh compartment, along with elevated expression of
PD-1, a key regulator of GC cell survival, is strongly associated with SLE disease
activity. Thus, Tfh population may be an attractive candidate for the monitoring and
treatment of SLE disease flares. We have also described, for the first time, the altered
composition of Tfh subsets in SLE and revealed another dimension of Tfh dysregulation
previously not appreciated. These data provide a basis to better elucidate the dynamics of
pathological Tfh activity in human SLE.
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FIGURE LEGENDS
Figure 1. Prevalence of circulating cells with Tfh phenotype (CXCR5hiICOShiPD-1hi) in
blood samples of healthy controls (H; n = 16), patients with Behçet's disease (BD; n =
28), and patients with systemic lupus erythematosus (SLE; n = 49). A, Representative
fluorescence-activated cell sorter (FACS) analysis of circulating lymphocytes, gated on
viable CD4+TCRβ+ cells (left panel), plus CD45RA+ cells (naïve subset), CD45RACXCR5lo cells (CXCR5lo subset), and CD45RA-CXCR5hi cells (CXCR5hi subset).
Representative expression of ICOS and PD-1 in naïve subset; value in naïve subset gate
(ICOShiPD-1hi [black box]) is the percentage of viable lymphocytes (right panel). B,
Representative FACS analysis of ICOS and PD-1 expression in the CXCR5hi subset from
healthy peripheral blood mononuclear cells (PBMC; left panel), SLE PBMC (middle
panel), and Tonsil (right panel). Values in the compartments (black box) are the
percentages of ICOShiPD-1hi cells. C, Expansion of ICOShiPD-1hi cells in CXCR5hi and
CXCR5lo subset in SLE patients, but not in BD patients or healthy controls. Statistical
analysis was performed using One-way ANOVA (*** p < 0.001). D, Correlation
between PD-1 and ICOS expression (mean fluorescence intensity; MFI) in CXCR5hi
(Pearson r = 0.38, p = 0.03), but not CXCR5lo (Pearson r = 0.10, p = 0.59) subset. Data
points represent individual subjects; horizontal lines represent the mean value with
standard error of the mean.
Figure 2. Expression of follicular helper T cell (Tfh) surface receptors in circulating
CD4+ lymphocytes of healthy controls (H), patients with Behçet's disease (BD), and
patients with systemic lupus erythematosus (SLE). A, similar ICOS expression (MFI) in
CXCR5hi and CXCR5lo subset in SLE patients as compared to healthy control. B,
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elevated PD-1 expression (MFI) in CXCR5hi and CXCR5lo subset in SLE patients as
compared to healthy control and BD patients. Data points represent individual subjects;
horizontal lines represent the mean value with standard error of the mean. Statistical
analysis was performed using One-way ANOVA. (* p < 0.05; ** p < 0.01; *** p <
0.001; n.s. no significance). See figure 1 for additional definitions.
Figure 3. PD-1 expression on circulating CXCR5hi subset correlates with Systemic
Lupus Erythematosus Disease Activity Index (SLEDAI) and expansion of circulating
plasmablasts. A, No association between percentages of activated CXCR5hi subset in
circulating CD4+ T cells and SLEDAI (Spearman r = - 0.21, p = 0.28) in systemic lupus
erythematosus (SLE) patients with active disease. B, Significant correlation between PD1 MFI in circulating CXCR5hi subset and clinical activity as measured by SLEDAI
(Spearman r = 0.43, p = 0.03) in SLE patients with active disease. C, No association
between ICOS MFI in CXCR5hi subset and SLEDAI (Spearman r = 0.16; p = 0.52) in
SLE patients with active disease. D, expansion of circulating plasmablast (CD19+IgDCD38+) in SLE patients as compared to Behçet's disease (BD) and healthy control (H).
Statistical analysis was performed using One-way ANOVA (* p < 0.05). E, Correlation
between percentage of circulating plasmablasts and PD-1 MFI in blood activated
CXCR5hi subset (CD45RA-CXCR5hi) in SLE patients (Spearman r = 034; p = 0.02; left
panel). Percentage of circulating plasmablasts in the presence or absence of prednisone,
antimalarial, and azathioprine treatments in the SLE patient cohort. Statistical analysis
was performed using Student’s t test (n.s. = no significance). Data points represent
individual subjects; horizontal lines represent the mean values with standard error of the
mean.
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Figure 4. Functional and phenotypic analysis of circulating CXCR5hiPD-1hi cells. A,
Representative FACS analysis of intracellular IL-21 staining in circulating CXCR5hiPD1lo cells and CXCR5hiPD-1hi cells; values represent percentages of IL-21+ cells (left
panel). Increased percentage of IL-21+ cells in circulating CXCR5hi-PD-1hi population as
compared to CXCR5hiPD-1lo population (p = 0.02; right panel). B, Representative FACS
analysis of CCR7 expression in circulating naïve, CXCR5hiPD-1lo, and CXCR5hiPD-1hi
subsets; gating of PD-1hi and PD-1lo subset is based on PD-1 expression on circulating
naïve subset (left panel). Significant decrease in CCR7 expression in CXCR5hiPD-1hi
cells as compared to CXCR5hiPD-1lo cells (p = 0.03). CCR7 expression is represented as
relative CCR7 MFI to that of circulating naïve subset (right panel). C, Representative
histogram showing the expression of Bcl6 in SLE circulating CXCR5hiPD-1hi cells,
Tonsil naïve cells (CD4+TCRβ+CD45RA+), and Tonsil follicular helper T cells (Tfh;
CD4+TCRβ+CD45RA-CXCR5hiPD-1hi). Statistical analysis was performed using
Student’s t test.
Figure 5. Model of altered follicular helper T cell phenotype in systemic lupus
erythematosus. Presentation of autoantigen by dendritic cells (DC) to T cells leads to the
differentiation of T helper (Th) cells and follicular helper T precursors (preTfh). Tfhdestined cells migrate to border of T-cell zones and B-cell follicles, where they contact
autoantigen-activated B cells. Subsequent migration of both subsets deeper into the
follicle leads to germinal center (GC) formation. GC Tfh cells are notable for high
CXCR5, PD-1, and Bcl6 expression, as well as production of IL-21. In the GC, Tfh cells
promote class switching and affinity selection of B cells via secretion of cytokines (eg.
IL-21) and expression of cell bound molecules (eg. PD-1). The result is the production of
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high-affinity autoantibody-secreting plasma cells, leading to pathology and disease
activity. In parallel, there is an expansion of Tfh-like cells in the peripheral blood. Akin
to Tfh cells, these Tfh-like cells also express high levels of CXCR5 and PD-1, and are
enriched with IL-21 producers. High PD-1 expression in blood Tfh-like cells is
associated with disease activity, plasmablast expansion, and autoantibody production.
Unlike GC Tfh cells, circulating Tfh-like cells have low levels of Bcl6, indicating that
they may have relocated to the periphery pre- or post-germinal center reaction.
Importantly, these circulating Tfh-like cells express low levels of CCR7, which
differentiate them from previously described central memory T cells with high level of
CXCR5.
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